• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

    2/1/24 7:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email

    Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations

    Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201589182/en/

    Deborah M. Autor, CEO of Healthcare Innovation Catalysts (Photo: Business Wire)

    Deborah M. Autor, CEO of Healthcare Innovation Catalysts (Photo: Business Wire)

    With over 30 of experience at the highest levels of government and regulated industry, Ms. Autor brings an unparalleled range of expertise across regulatory, quality, compliance, business strategy, policy, and law. Her government career spanned two decades, culminating in the crucial role of Deputy Commissioner of FDA where she oversaw all inspections and international operations. Her FDA tenure also included distinguished service as Director of the Office of Compliance in FDA's Center for Drug Evaluation and Research, where she led enforcement and policy making for compliance with all requirements relating to pharmaceuticals. Before FDA, Ms. Autor was a decorated federal prosecutor at the U.S. Department of Justice, and FDA was her client.

    In addition to this wealth of government experience, Ms. Autor has also been a hands-on leader of key functions in both the brand and generic pharmaceutical industries. She ran multiple regulatory functions for all AstraZeneca products globally and led Global Quality at Mylan, overseeing the quality of 60 billion doses of medicine annually across 50 manufacturing sites and dozens of regulatory systems.

    "We are honored to have Deb take the helm as our first CEO," stated Michael Singer, Executive Chairman of HIC. "She brings an unparalleled wealth of experience to HIC as a leader, strategist, and technical expert. Because she has played so many different roles in and around the life sciences industry, Deb brings a uniquely valuable perspective that will enable us to further leverage H.I.C.'s technical bench to achieve meaningful and groundbreaking results for our clients. She is highly regarded, widely recognized, and deeply connected."

    "I am delighted to join HIC's tremendous team. In its short year and half, HIC has produced amazing results for its clients and grown to be a formidable technical force and catalyst for healthcare innovation," said Ms. Autor. "I look forward to bringing my vision, knowledge, and government and industry know-how to HIC, with the ultimate goal of finding elegant solutions to clients' needs in areas such as product development, compliance, post-approval support, and federal partnerships."

    Ms. Autor has been a visible expert for many years. Since 2018, she has served as Chair of the FDA Alumni Association, where she continues to work to support the agency's mission. She is also a Non-Executive Director of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). She has testified in Congressional hearings and appeared in national and international print and television media, including the New York Times, Wall Street Journal, USA Today, LA Times, Boston Globe, NBC, ABC, CBS, and CNN.

    About Healthcare Innovation Catalysts, Inc.

    Healthcare Innovation Catalysts, Inc. (HIC) was founded in 2022 to fill a gap in the advisory services available to the global life sciences industry. Because we unite strategic and technical expertise with deep connections and knowledge, HIC is uniquely suited to help our clients envision and reach daunting goals and overcome appreciable obstacles. We are a catalyst for healthcare innovation. Rather than stopping at the surface or drowning in the weeds, we unify multiple levels of analysis to create clear, actionable deliverables, enabling our clients to meet otherwise elusive goals and solve intractable problems pre- and post-market. Our organization includes experts from government, industry, and academia across disciplines, including regulatory affairs, clinical advisory, biostatistics, quality, compliance, and federal partnerships. Among many other things, we have brought novel drugs, biotech products, and medical devices through the clinical development and approval processes; audited clinical trials, manufacturing sites, and labs; developed federal partnerships; and resolved significant compliance problems.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240201589182/en/

    Get the next $AMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    SEC Filings

    See more
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/8/25 4:21:09 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.

      10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/7/25 4:39:31 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/2/25 6:18:24 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

      Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      6/6/25 8:33:10 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by Analyst with a new price target

      Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      2/24/25 7:02:03 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00

      9/6/24 7:29:08 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/18/25 4:11:43 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Patel Gautam sold $452,537 worth of shares (56,426 units at $8.02), decreasing direct ownership by 3% to 1,704,050 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/12/25 4:19:17 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Vice President Shah Nikita sold $372,481 worth of shares (49,140 units at $7.58), decreasing direct ownership by 11% to 388,929 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      5/19/25 4:16:23 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

      Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compare

      6/25/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

      Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-respo

      6/12/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Participate at Upcoming Investor Conferences in June

      BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events. About AmnealAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered

      5/29/25 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

      Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif

      4/11/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

      - Celebrating Amneal's recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation a

      3/28/24 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

      Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors. This press rele

      2/1/24 7:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Financials

    Live finance-specific insights

    See more
    • Amneal Reports First Quarter 2025 Financial Results

      ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT® for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to pat

      5/2/25 6:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Report First Quarter 2025 Results on May 2, 2025

      Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call

      4/8/25 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

      ‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒ ‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒ ‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) – Amneal Pharmaceuticals,

      2/28/25 6:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

      SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      11/14/24 4:11:34 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

      SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      10/31/24 6:51:29 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      5/13/24 4:15:28 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care